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Fetal overgrowth in pregnancies complicated by diabetes is the result of an increased substrate availability which stimulates fetal
insulin secretion and fetal growth. However, despite strict glycemic control in modern clinical management of the pregnant wom-
an with diabetes, fetal overgrowth remains an important clinical problem. Recent studies in vivo provide evidence for increased
delivery of amino acids to the fetus in gestational diabetes (GDM) even when metabolic control is strict. This could be due to that
truly normal maternal substrate levels cannot be achieved in diabetic pregnancies and/or caused by altered placental nutrient
transport and metabolism. Studies in vitro demonstrate an up-regulation of placental transport systems for certain amino acids
in GDM associated with fetal overgrowth. GDM is also characterized by changes in placental gene expression, including up-
regulation of inflammatory mediators and Leptin. In type-I diabetes with fetal overgrowth the in vitro activity of placental trans-
porters for both glucose and certain amino acids as well as placental lipoprotein lipase is increased. Furthermore, both clinical
observations in type-I diabetic pregnancies and preliminary animal experimental studies suggest that even brief periods of met-
abolic perturbation early in pregnancy may affect placental growth and transport function for the remainder of pregnancy, thereby
contributing to fetal overgrowth. Ultrasound measurements of fetal fat deposits and abdominal circumference as well as 3D
ultrasound assessment of placental volume represent non-invasive techniques for in utero diagnosis of fetal and placental over-
growth. It is proposed that these methods represent valuable additions to the clinical management of the diabetic pregnancy.
In conclusion, altered placental function may be a mechanism contributing to fetal overgrowth in diabetic pregnancies with
apparent optimal metabolic control. It is proposed that detailed information on placental metabolism and transport functions
obtained in vitro and in vivo represent a placental phenotype that provides important information and may facilitate diagnosis
and improve clinical management of fetal overgrowth.
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In a brief introductory note, Jansson pointed out that fetal over-
growth, resulting in the delivery of a large-for-gestational age
baby (LGA), represents a risk factor for operative delivery, trau-
matic birth injury and developing diabetes and obesity later in
life. Fetal overgrowth is a common pregnancy complication
and for example in theUS, a birth weight> 4000 gwas recorded
in 7.9%of all deliveries in 2003, corresponding to approximately
300,000 babies [1]. Fetal overgrowth may occur in pregnancies
complicated by maternal diabetes despite rigorous glycemic
* Corresponding author. Department of Obstetrics and Gynecology,
University of Cincinnati, College of Medicine, 231 Albert Sabin Way,
PO Box 670526, Cincinnati, OH 45267, USA.
E-mail address: thomas.jansson@uc.edu (T. Jansson).0143e4004/$esee front mattercontrol in modern clinical management of these patients. This
could be due to that truly normal maternal substrate levels can-
not be achieved in diabetic pregnancies and/or caused by altered
placental nutrient transport and metabolism. We will briefly re-
view recent clinical and experimental studies, suggesting that al-
terations in the activity of placental nutrient and ion transporters
and changes in placental metabolism may contribute to fetal
overgrowth in diabetes. The possible clinical implications of
these findings will be discussed and important directions for fu-
ture research will be identified.
MACROSOMIA, LGA, EXCESS FETAL
GROWTH AND FETAL OVERGROWTH
Many fetuses in pregnancies complicated by diabetes display
accelerated intrauterine growth, so their birth weight exceeds 2006 Published by IFPA and Elsevier Ltd.
S110 Placenta (2006), Vol. 27, Supplement A, Trophoblast Research, Vol. 20the normal range. Definitions of this condition at birth have
been macrosomia, if birth weight exceeds 4000 g, or LGA,
thus placing birth weight in relation to gestational age. As
for the opposite condition of intrauterine growth restriction,
Cetin argued that the change in growth trajectory can be dia-
gnosed in utero by ultrasound based on multiple records show-
ing an increasing abdominal circumference. However,
intrauterine growth patterns based on serial ultrasound meas-
urements have not been used in more strict definitions of
fetuses growing larger than defined by their genetic potential,
although many authors now refer to it as ‘‘excess fetal growth’’
or ‘‘fetal overgrowth’’.
INCREASED MATERNAL SUBSTRATE
LEVELS – AN INSUFFICIENT EXPLANATION
FOR FETAL OVERGROWTH?
Fetal growth is regulated by the balance between the fetal nu-
trient demand, determined by its genetic growth potential, and
the maternaleplacental supply. As discussed by Cetin, factors
that determine the maternaleplacental supply of nutrients in-
clude maternal nutrition and metabolism, the transplacental
concentration gradient, utero-placental blood flow, placental
size and its transfer capabilities. According to the Pedersen’s
hypothesis [2], fetal overgrowth in pregnancies complicated
by diabetes is the result of increased substrate availability to-
gether with a permissive endocrine environment that ultimately
will lead to increased adiposity. In this model, increased ma-
ternal levels of glucose as well as amino acids and lipids are
transferred to the fetus and stimulate fetal hyperinsulinemia
[2]. Normal maternal glucose levels have usually been consid-
ered as the main target of any protocol for the management
of pregnancies complicated by gestational diabetes. Neverthe-
less, the incidence of macrosomia is increased in GDM de-
spite an optimal glycemic control. This may be due to an
inability of the standard measurements of glucose control to
identify periods of moderate hyperglycemia that are sufficient
to increase fetal glucose availability. An additional possibility
is that changes in placental nutrient transfer capacity and me-
tabolism contribute to fetal overgrowth in diabetic pregnan-
cies. Increased placental weights and placental ratios
(placental weight to birth weight ratio) have been reported
in pregnancies complicated by GDM [3], even in the pres-
ence of optimal maternal glycemic control throughout the
third trimester [4]. The increased placental mass could
then augment placental nutrient exchange by increasing the
surface area available for substrate transfer.
CLINICAL STUDIES INDICATE AN INCREASED
NUTRIENT DELIVERY TO THE FETUS
IN DIABETES
Cetin suggested that changes in placental nutrient transport,
due to increased exchange surface area or increased transporter
densities could further increase substrate levels and fetal
growth in diabetic pregnancies. Recent observations in vivodemonstrate that the umbilical delivery of amino acids is sig-
nificantly increased even in well controlled GDM pregnancies,
with maternal substrate levels comparable to those observed in
normal pregnancies [5]. These changes in fetalematernal rela-
tionships are opposite to those which have been reported in
pregnancies associated with intrauterine growth restriction
[6]. Previous studies using in vitro perfused placenta have sug-
gested unaltered glucose transfer in the maternalefetal direc-
tion in GDM [7]. Recent preliminary data show that fetuses
of GDM mothers have an increased glucose concentration in
both umbilical vein and artery despite a good maternal glyce-
mic control and normal maternal glucose levels [8]. Further
in vivo studies involving stable isotope techniques will provide
more conclusive evidence as to whether placental glucose
transfer capacity is altered in well controlled GDM
pregnancies.
Studies of body composition have shown that fetal fat depo-
sition and neonatal fat mass are significantly increased in in-
fants of women with GDM [9,10]. Therefore, ultrasound
parameters indicative of the size of fetal fat deposits in utero
have recently been proposed as markers of abnormal fetal
growth that could be used in the clinical management of dia-
betes in pregnancy. Moreover, the possibility of evaluating
placental volume by 3D ultrasound in utero in the first half
of pregnancy should be considered in pregnancies with type-
I diabetes and in women with increased risk of developing
GDM. Fetal and placental growth criteria could then be
used for determining clinical management of diabetes in preg-
nancy, avoiding unnecessary intervention in low risk pregnan-
cies and intensifying therapy and controls in those showing
alterations of fetal growth.
UP-REGULATION OF PLACENTAL
NUTRIENT TRANSPORTERS IN VITRO
AND THE POSSIBLE ROLE OF INSULIN
The reported alterations in placental transporter activity and
expression, measured in vitro, in association to maternal diabe-
tes and fetal overgrowth were reviewed by Powell. Glucose
transport activity and glucose transporter isoform 1 (GLUT 1)
expression have been shown to be increased in the syncytio-
trophoblast basal plasma membrane (BM) isolated from preg-
nancies complicated by type-I diabetes [11]. Since glucose
transport across BM represents the rate-limiting step in
transplacental glucose transfer, these changes may result in
an increased glucose flux to the fetus even when maternal
glucose levels are maintained within the normal range. In
contrast, GDM with LGA was not associated with changes
in placental glucose transporting capacity [12]. Neutral amino
acid transport capacity by System A is increased in both
GDM and type-I diabetes with LGA, whereas the activity
of placental transporters for the essential amino acid leucine
is increased in GDM only [13]. In contrast, a previous study
indicated that System A activity is reduced and the activity
of system L is unaltered in microvillous plasma membrane
vesicles isolated from type-I diabetic pregnancies with LGA
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were that they were carried out in different populations and
that placental weight was increased in parallel to fetal weight
in one study [13] whereas placental weight was largely unaf-
fected in the other [14]. Thus, the placental response to met-
abolic disease may differ between study populations although
outcome with regard to fetal weight is the same. Other nutri-
ent transport systems such as those associated with transpla-
cental calcium (calcium pump in BM, [15]) and lipid
(lipoprotein lipase in MVM, [16]) transport also show
changes in placentas of type-I diabetic pregnancies in associ-
ation with fetal overgrowth but not in cases of GDM. Re-
cently, preliminary data have also been presented showing
increased placental expression of SR-BI, a cholesterol trans-
porter, in well controlled GDM pregnancies [17].
Differences in placental transport capacity in type-I diabe-
tes/LGA vs GDM/LGA pregnancies suggest a potential
role of insulin as a mediator of placental transport alterations.
Studies demonstrating insulin regulation of placental transport
function in villous explant culture include increased System A
activity in term villous tissue [18] and increased glucose trans-
port capacity in first trimester only [19]. Preliminary data sug-
gest a possible role of insulin in regulating some aspects of ion
(Na/H exchanger) and lipid (lipoprotein lipase) transport in
cultured trophoblast cells. Taken together, the up-regulation
of placental transporters for the primary nutrients in diabetes,
possibly due to insulin regulation, provides an explanation for
the occurrence of large babies in these pregnancies despite
‘‘normal’’ maternal blood-glucose levels. However, LGA
fetuses also occur in GDM pregnancies without insulin ad-
ministration and in the absence of a change in the placental
transport functions observed in type-I diabetes. Clearly a vari-
ety of mechanisms lead to similar outcomes and additional in-
formation on the control of placental nutrient transport
function and its role in regulating fetal growth are needed.
INSULIN CONTROL OF PLACENTAL FUNCTION
SHIFTS FROM MOTHER TO FETUS OVER
THE COURSE OF PREGNANCY
The role of insulin in the pathophysiology of fetal overgrowth
is unlikely to be limited to effects on placental transport. Des-
oye argued that diabetes-associated hyperinsulinemia in the
maternal and fetal circulation may have profound effects on
placental development and function at different time periods
in gestation. Placental insulin sensitivity changes in time and
location from the trophoblast in the first trimester to the endo-
thelium at the end of gestation [20,21]. This will allow fetal
insulin to affect the placenta directly by interacting with the
insulin receptors on the placental endothelium. Indirectly,
fetal insulin may induce changes in the fetus proper that will
then act back on the placenta. Examples of such direct and in-
direct effects are stimulation of placental glycogen synthesis
and angiogenesis via insulin-induced fetal hypoxia [22],
respectively.GDM IS ASSOCIATED WITH MARKED
ALTERATIONS IN PLACENTAL
GENE EXPRESSION
Fetal overgrowth in GDM has been associated with an in-
creased risk to develop obesity and type-2 diabetes in later
life [23]. Maternal anthropometric factors together with the
maternal carbohydrate metabolism have been highly correlated
with fetal growth and body composition [24]. However, these
factors can explain only part of the fetal fat mass variance, sug-
gesting that other mechanisms may be involved [24] such as
altered placental function. The effect of GDM on placental
gene expression has not been widely studied. Radaelli reported
studies in which the gene expression profile of term placenta
from women with normal glucose tolerance and with GDM
was investigated using oligonucleotide microarray analysis
[25]. Twenty percent of the significantly modified genes iden-
tified in GDM placentas were related to inflammatory re-
sponse and extracellular matrix, including TNF-a, Leptin,
IL-1, Endothelin-1 and Angiotensin-2 genes which were sig-
nificantly up-regulated. Other significantly regulated genes in
the GDM placenta were related to lipid metabolism primarily
encoding rate-limiting enzymes for fatty acid transport, tri-
glycerides and cholesterol synthesis. Based on these data, it
is suggested that there is a link between insulin resistance dur-
ing pregnancy and the inflammatory response originating at
the level of placental gene transcription while the increase in
placental lipid biosynthetic pathways has functional signifi-
cance for fetal fat accretion as a step towards enhanced placen-
tal transfer of FFA [25].
THE ROLE OF BRIEF PERIODS OF METABOLIC
PERTURBATIONS IN EARLY PREGNANCY
FOR FETAL OVERGROWTH
Even in the strictly controlled pregnant woman with type-I
diabetes, glucose control may be sub-optimal early in pregnan-
cy. Indeed, maternal first trimester HbA1c correlates strongly
to birth weight [26]. However, the mechanisms underlying
this association are unknown. Ericsson discussed a series of ex-
periments in the pregnant rat designed to test the hypothesis
that brief periods of hyperglycemia early in pregnancy may af-
fect placental transport functions for the remainder of gesta-
tion, resulting in fetal overgrowth [27]. Transient moderate
hyperglycemia in early pregnancy increased placental and fetal
weights at term. The in vivo placental System A activity was
significantly decreased whereas placental glucose transport
was unaltered at term. In concert with this data, placental pro-
tein expression of the System A isoform SNAT 2 was de-
creased and placental GLUT 1 and 3 expression unchanged.
These studies demonstrate that brief periods of metabolic per-
turbations early in pregnancy can alter placental transport
functions and placental and fetal growth for the duration of
pregnancy. The underlying mechanisms remain to be estab-
lished but may be related to the increased placental size or
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tial amino acids) not assessed in the study.
STUDY POPULATIONS NEED TO BE BETTER
CHARACTERIZED IN FUTURE STUDIES
The placenta undergoes a variety of structural [28] and func-
tional [22] changes in maternal diabetes. As pointed out by
Desoye, it is unclear whether these changes are the primary re-
sponse of the placenta to the adverse diabetic environment in
the mother, or secondary to alterations in the fetus in the wake
of maternal diabetes. These changes may protect the fetus
from maldevelopment, or may contribute to, or even promote,
the diabetes-associated increased incidence of fetal morbidity
or mortality. A clear answer to these questions is yet pending,
because studies do not report on the many variables that may
have an impact on the placenta studied at term in diabetic
pregnancy. These variables include the quality of metabolic
(glycemic) control of mother and fetus, the type of diabetes
(type-I/-II vs gestational diabetes), the modality of treatment
(oral hypoglycaemic agents, insulin, diet), pre-existing vascular
complications in the mother, maternal obesity and fetal out-
come in terms of oxygenation. The influence of some of these
factors may vary with time e.g., the onset of insulin therapy in
gestational diabetics may influence the placental changes as
may the quality of maternal metabolic control not only in
the third trimester, but also in earlier periods of gestation.
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